NAD+ boosters: NMN & NR

Give this side its full due, because it is real. In randomized, placebo-controlled human trials, nicotinamide riboside reliably increases blood NAD+ in a dose-dependent way and is well tolerated.¹ Longer trials confirm the rise is sustained over weeks, with hints — not proof — of downstream effects like a small drop in blood pressure in one subgroup.² NMN shows the same core result: it raises NAD+ metabolites, and one trial in prediabetic women reported improved muscle insulin sensitivity, a biomarker outcome.⁴ The most recent randomized NMN trial, published in September 2026, confirms it at a high dose: in adults aged 65 and older, 1,250 mg of NMN a day for 24 weeks significantly raised whole-blood NAD+ and related metabolites compared with placebo, and was generally well tolerated.⁵ So if your question is narrowly “does this pill raise the molecule it claims to?” the answer is yes. That already puts NAD+ boosters ahead of most of this shelf.

Here is the part the ads skip. Raising a biomarker is not the same as improving your health, and NAD+ is a textbook case of the difference. No human trial has shown that boosting NAD+ makes people age more slowly, think more clearly or live longer. Where trials did look at function, the picture is mixed. Single small trials report, as secondary outcomes, a faster 4-metre walk after 12 weeks of 250 mg NMN in older adults, or a longer six-minute walk after 60 days in healthy middle-aged adults.⁸⁹ But a pooled analysis of randomized trials found that NMN had no significant effect on muscle mass index, grip strength or gait speed,¹⁰ and a 2026 systematic review of 33 human studies concluded that effects on functional, metabolic and other health outcomes were heterogeneous and often null, so clinical effectiveness for anti-aging or wellness remains inconclusive.⁷ The studies are small (often dozens of people) and short (weeks to a few months). The dramatic results — restored fur, better endurance, longer life — are almost all in mice. Betting that mouse lifespan data transfer to humans is exactly the bet resveratrol lost.

The September 2026 NMN trial fits that pattern. Its primary endpoint was hearing (auditory function), and 24 weeks of 1,250 mg NMN did not improve it, nor did it improve the physical performance measures. Some changes in body composition, blood fats and eating behavior showed up nominally but did not hold after correction for multiple testing, so the authors treat them as exploratory.⁵ Worth knowing when you weigh it: the trial was funded by MIRAILAB BIOSCIENCE, which also supplied the NMN. Three of the authors work for the company (the disclosure lists one as its CEO), though the paper states that the company was not involved in study design, data collection, analysis or writing.

NAD+ precursors have also been tested against a serious disease. The NOPARK trial (JAMA, October 2026) gave nicotinamide riboside, 500 mg twice daily for 52 weeks, to 410 people with early Parkinson disease. It found no benefit; on the main symptom score the placebo group did slightly better (a difference of 2.7 points on a 0–236 scale).¹¹ That is a different compound and a different condition, so it says nothing direct about NMN in healthy older adults — but it is a reminder that a higher NAD+ level does not guarantee a clinical payoff. Until a proper trial measures something that matters and finds it, the correct verdict is “plausible, unproven.”

Is NMN allowed as a supplement ingredient in the US? Yes, since 29 September 2025. NMN had a turbulent status before that: in 2022 the FDA concluded that, because NMN had been authorized for investigation as a new drug, it was excluded from the legal definition of a dietary supplement — effectively telling sellers it should not be marketed as one. In letters dated 29 September 2025, responding to citizen petitions, the FDA reversed course and confirmed that NMN is not excluded from the definition of a dietary supplement, because there was enough evidence that it was sold as a supplement in the US before the drug authorization.³ The FDA has since reinstated earlier safety notifications for NMN.¹²

Does that make every NMN product compliant? No — that is a separate question, decided product by product. NMN is still treated as a new dietary ingredient, so a company must file a safety notification (an NDI notification) with the FDA before marketing it, unless it buys from a supplier that has already done so. A product sold without one can still be treated as adulterated.³ Legal commentators also point out that the FDA’s reading could be challenged in court or revised by a later administration.³ What has not changed is quality: purity and actual NMN content vary a lot between brands, so third-party testing matters more than the regulatory label. NR was never caught in this dispute — it is an established, notified supplement ingredient.

Trial doses run roughly 250–1,000 mg/day for NR, and 250–2,000 mg/day for NMN (the September 2026 trial used 1,250 mg). Both look safe and well tolerated over the months studied: a 2026 meta-analysis of randomized NMN trials (doses of 250–2,000 mg/day, up to 24 weeks) found no increase in overall or serious adverse events and no rise in the liver enzymes ALT and AST.⁶ What we lack is long-term data, and the trials are mostly short. If you want to experiment with a marker you can even measure, that is a defensible personal choice — pick a brand that publishes third-party testing, and be clear-eyed that you are buying a raised number, not a proven benefit. With the US regulatory question for NMN largely settled, choose between NR and NMN on testing and price rather than on legal status. What you should not do is treat either as established anti-aging medicine, spend heavily on it, or let it displace the things with real outcome evidence: exercise, protein, sleep.